Paul Stone compensation by year
IDEAYA Biosciences Summary Compensation Table · all 5 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Salary | $327,250 | $374,500 | $394,000 | $419,000 | $432,024 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 |
| Option awards | $180,964 | $396,832 | $1,251,344 | $880,637 | $1,779,204 |
| Non-equity incentive | $103,000 | $123,585 | $146,940 | $161,734 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $1,800 | $10,350 | $10,500 | $10,950 | $14,775 |
| Total | $613,014 | $905,267 | $1,802,784 | $1,472,321 | $2,226,003 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IDEAYA Biosciences, Inc. DEF 14A filed April 19, 2024, accession 0000950170-24-045724, and prior-year filings. Open the filing on EDGAR.
How this page was built: the IDEAYA Biosciences, Inc. filed document, accession 0000950170-24-045724. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2024.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 16,243 | — | $4.62 |
| Option | 6,825 | — | $11.08 |
| Option | 41,667 | — | $6.92 |
| Option | 80,000 | — | $19.52 |
Per the Outstanding Equity Awards at Fiscal Year-End table in IDEAYA Biosciences, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
IDEAYA Biosciences’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Yujiro Hata | President and Chief Executive Officer | $5,995,440 |
| Michael White | Chief Scientific Officer | $2,758,719 |
| Paul Stone · this page | Former Chief Financial Officer | $2,226,003 |
| Jason Throne | Chief Legal Officer | $1,869,660 |
| Darrin Beaupre | Chief Medical Officer | $1,809,351 |
| Andres Ruiz Briseno | Senior Vice President, Head of Finance and Investor Relations | $1,412,542 |
The full IDEAYA Biosciences compensation record
free company briefThis page is one person within IDEAYA Biosciences's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the IDEAYA Biosciences proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IDEAYA Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.